AstraZeneca trial pause not worrisome because we have many vaccine options: Expert
Exiger Global Markets President Brandon Daniels on the development of a coronavirus vaccine.
ZURICH/FRANKFURT (Reuters) – AstraZeneca should still know before the end of the year whether its experimental vaccine protects people against COVID-19, the drugmaker’s chief executive Pascal Soriot said on Thursday, as long as it can resume trials soon.
Continue Reading Below
The British company suspended late-stage trials this week after an illness in a participant in Britain. The patient was reportedly suffering from symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.
ASTRAZENECA CORONAVIRUS VACCINE PAUSE 'NOT NECESSARILY' A SETBACK: UK HEALTH MINISTER
Soriot said during an online event that AstraZeneca did not yet know the diagnosis, adding that it was not clear if the volunteer had transverse myelitis and more tests were needed.